Rawat Swapnil, Yadav Ramasheesh, Goyal Siddhi, Nagpal Jitender
Sitaram Bhartia Institute of Science and Research, B-16 Qutub Institutional Area, New Delhi, 110016, India.
Sitaram Bhartia Institute of Science and Research, B-16 Qutub Institutional Area, New Delhi, 110016, India.
Diabetes Metab Syndr. 2023 Nov;17(11):102880. doi: 10.1016/j.dsx.2023.102880. Epub 2023 Oct 12.
Despite high prevalence and ethnic susceptibility, limited published estimates are available on long term complication risks among known diabetes patients in India. Hence, we undertook evaluation of the cardiovascular risk of known diabetes patients from Delhi.
The community-survey was conducted using a probability-proportionate-to-size(systematic) 2-stage cluster design. Thirty areas were selected for a house-to-house survey to recruit 25 to 30 subjects (known diabetes ≥1 year; 35-65 years of age) per area. Scores from the UKPDS 2.1, UKPDS 2.0, Framingham, ASCVD, WHO, NHS and SCORE studies were used for 10-year risk calculation.
We enrolled 843 subjects of which 800 consented for blood sampling. The mean age of the subjects was 53.0(52.1-54.0) years, the mean duration since diagnosis was 7.1(6.7-7.5) years, with 49.8 % women. 61.8 % were hypertensive, 81.5 % were dyslipidaemic and 53.3 % had poor glycaemic control. Although variable, risk engines estimates were consensual in projecting a high ten-year Coronary-Heart-Disease risk of 10-16 %, a stroke risk of 3.7-5.0 %, and a 5.0-5.7% risk of cardiovascular fatality. These risks were 1.5-3 times the 'risk at target levels' suggesting mitigability. Only 9.3 %, 16.0 %, and 30.0 % were taking aspirin, lipid lowering drugs and antihypertensives respectively.
The study highlights the impending impact of, and the scope for improvement in the cardiovascular risk profile of diabetes patients in Delhi, including the use of cardioprotective medications. It strengthens the case for developing and testing potential interventions for improvement.
尽管糖尿病患病率高且存在种族易感性,但关于印度已知糖尿病患者长期并发症风险的公开估计数据有限。因此,我们对德里已知糖尿病患者的心血管风险进行了评估。
社区调查采用按规模大小成比例的(系统)两阶段整群设计。选择30个区域进行逐户调查,每个区域招募25至30名受试者(已知糖尿病≥1年;年龄35 - 65岁)。使用英国前瞻性糖尿病研究(UKPDS)2.1、UKPDS 2.0、弗雷明汉、动脉粥样硬化性心血管疾病(ASCVD)、世界卫生组织(WHO)、美国国立卫生研究院(NHS)和系统性冠状动脉风险评估(SCORE)研究的评分来计算10年风险。
我们招募了843名受试者,其中800名同意进行血液采样。受试者的平均年龄为53.0(52.1 - 54.0)岁,自诊断以来的平均病程为7.1(6.7 - 7.5)年,女性占49.8%。61.8%患有高血压,81.5%血脂异常,53.3%血糖控制不佳。尽管风险评估工具的估计值存在差异,但在预测10年冠心病高风险为10% - 16%、中风风险为3.7% - 5.0%以及心血管死亡风险为5.0% - 5.7%方面是一致的。这些风险是“目标水平风险”的1.5至3倍,表明具有可缓解性。分别只有9.3%、16.0%和30.0%的患者正在服用阿司匹林、降脂药物和抗高血压药物。
该研究突出了德里糖尿病患者心血管风险状况即将产生的影响以及改善的空间,包括使用心脏保护药物。这强化了开展和测试潜在改善干预措施的理由。